STATEX DROPS 20MG/ML

Negara: Kanada

Bahasa: Inggris

Sumber: Health Canada

Bahan aktif:

MORPHINE SULFATE

Tersedia dari:

PALADIN LABS INC.

Kode ATC:

N02AA01

INN (Nama Internasional):

MORPHINE

Dosis:

20MG

Bentuk farmasi:

DROPS

Komposisi:

MORPHINE SULFATE 20MG

Rute administrasi :

ORAL

Unit dalam paket:

25ML/100ML

Jenis Resep:

Narcotic (CDSA I)

Area terapi:

OPIATE AGONISTS

Ringkasan produk:

Active ingredient group (AIG) number: 0104545002; AHFS:

Status otorisasi:

CANCELLED POST MARKET

Tanggal Otorisasi:

2018-09-18

Karakteristik produk

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
STATEX
®
morphine sulfate
Oral Drops – 20 and 50 mg/mL
Suppositories – 5, 10, 20 and 30 mg
Oral Syrup – 1, 5 and 10 mg/mL
Tablets – 5, 10, 25 and 50 mg
Opioid Analgesic
Paladin Labs Inc.
100 Alexis Nihon Blvd., Suite 600
St-Laurent, Quebec
H4M 2P2
Date of Preparation:
December 4, 1985
Date of Revision:
April 5, 2018
Version: 5.0
Submission Control No: 211412
_ _
_STATEX_
_®_
_ _
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
.....................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................21
SPECIAL HANDLING INSTRUCTIONS
.......................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................22
PART II: SCIENTIFIC INFORMATION
...............................................................................24
PHARMACEUTICAL INFORMATION
..........................................................................24
DETAILED PHARMACOLOGY
................................